Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative CarePsyence Group2024-10-25T09:35:57+02:00October 25, 2024|Read More
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) DevelopmentPsyence Group2024-10-17T16:03:47+02:00October 17, 2024|Read More
Psyence Biomed Provides Update on Previously Announced Acquisition of ClairvoyantPsyence Group2024-10-08T08:37:35+02:00October 7, 2024|Read More
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabsPsyence Group2024-09-19T18:49:07+02:00September 19, 2024|Read More
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data MilestonesPsyence Group2024-09-16T13:49:07+02:00September 16, 2024|Read More
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from NasdaqPsyence Group2024-09-16T13:55:07+02:00September 14, 2024|Read More
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative CarePsyence Group2024-09-12T08:28:18+02:00September 11, 2024|Read More
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer ClairvoyantPsyence Group2024-09-09T16:53:12+02:00September 9, 2024|Read More
Psyence Biomed Announces Worldwide Exclusive Licensing Agreement with PsyLabs to Supply Nature-Derived Psilocybin to be Evaluated as a Potential Treatment for Alcohol Use Disorder (AUD) and Other Substance Use Disorders (SUDs)Psyence Group2024-09-04T15:02:32+02:00September 4, 2024|Read More
